

Si inoltra una nuova comunicazione dell' AIFA che annulla quella precedentemente inviata (venerdì 16 aprile 2021) - "PQ-PhCC/QDF/P/NUOVO INVIO:SI PREGA DI NON TENER CONTO DELL'ALLEGATO Nr. 1 INVIATO ERRONEMAMENTE DAL SISTEMA -PROVVEDIMENTO: RITIRO A SEGUITO SEGNALAZIONE DITTA ai sensi dell'art. 70 del D. L.vo 219/2006 DEL MEDICINALE "CEFIXINA AUROBINDO 400 mg compresse rivestite con film" AIC n. 044331015 prot. 0046337-16/04/2021-AIFA-AIFA_PQ_PhCC-P della ditta Aurobindo Pharma Italia Srl#168257045#".

Si chiede alle SS. LL. in indirizzo di darne la massima diffusione.
Distinti saluti.

Direttore
Direzione Farmaceutico-Protesica-Dispositivi medici
Dott.ssa Giovanna Scroccaro

Referente
dott.ssa Paola Deambrosis
tel.041.2791380
mail: paola.deambrosis@regione.veneto.it

REGIONE del VENETO

Area Sanità e Sociale

Segreteria Direzione Farmaceutico - Protetica - Dispositivi medici

Rio Novo, Dorsoduro 3493 - 30123 Venezia

Tel. 041.2793412 - 3415 - 3406 fax 041-279 3468

e-mail: assistenza.farmaceutica@regione.veneto.it

PEC: area.sanitasociale@pec.regione.veneto.it



GMP Compliance Menu

Search

[GMP Certificates](#)
[Non-Compliance Report](#)

 Exclude Teleconference info

Swissmedic, Swiss Agency for Therapeutic Products

Report No : **CH20-0566**

STATEMENT OF NON-COMPLIANCE WITH GMP

Exchange of information between National Competent Authorities (NCAs) of the EEA following the discovery of serious GMP non-compliance at a manufacturer

Part 1

Issued under the provisions of the Mutual Recognition Agreement between the European Union and **Switzerland**

The competent authority of Switzerland confirms the following:

The manufacturer : **Legacy Pharmaceuticals Switzerland GmbH**

Site address : **Rührbergstrasse 21, Birsfelden, 4127, Switzerland**

DUNS Number : **48-371-8149**

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2020-08-28** , it is considered that **it does not comply with the Good Manufacturing Practice** requirements referred to in The Good Manufacturing Practice requirements referred to in the Agreement of Mutual Recognition between the European Union and **Switzerland**

Part 2

Human Medicinal Products

Veterinary Medicinal Products

Human Investigational Medicinal Products

1 NON-COMPLIANT MANUFACTURING OPERATIONS
1.1 Sterile products
<p>1.1.1 <i>Aseptically prepared (processing operations for the following dosage forms)</i></p> <p>1.1.1.1 Large volume liquids</p> <p>1.1.1.3 Semi-solids</p> <p>1.1.1.4 Small volume liquids</p> <p>1.1.1.6 Other: Aseptic lyophilisation of sterile bulk and aseptic filling of sterile powder(en)</p> <p>1.1.2 <i> terminally Sterilised (processing operations for the following dosage forms)</i></p> <p>1.1.2.1 Large volume liquids</p> <p>1.1.2.3 Small volume liquids</p> <p>1.1.3 <i>Batch certification</i></p>
1.3 Biological medicinal products (list of product types)
<p>1.3.1 <i>Biological medicinal products (list of product types)</i></p> <p>1.3.1.6 Human or animal extracted products</p> <p>1.3.2 <i>Batch Certification (list of product types)</i></p> <p>1.3.2.6 Human or animal extracted products</p>

Manufacture of active substance. Names of substances subject to non-compliant :

[1]SWISSMEDIC LIST OF APIS, SEE 4 ACTIVE SUBSTANCES(en)

3. NON-COMPLIANT MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES	
Active Substance :SWISSMEDIC LIST OF APIS, SEE 4 ACTIVE SUBSTANCES	
3.2	Extraction of Active Substance from Natural Sources
	3.2.6 Purification of extracted substance Animal
3.4	Manufacture of sterile Active Substance
	3.4.1 Aseptically prepared

4. Non-Compliant Other Activities - Active Substances :

Sterile dry deproteinized dialysate of calf blood, Sterile Portamin HCL, any other sterile active pharmaceutical ingredient.

Part 3

<p>Nature of non-compliance :Swissmedic is updating the NCR as the situation has changed since the NCR has been issued. Legacy Pharmaceuticals Switzerland GmbH has filed for insolvency early December 2020 and is closed. Swissmedic has withdrawn the manufacturing licence with effect December 31, 2020. Swissmedic has issued a NCR on the 30.09.2020 related to the manufacture of sterile products after during a Swissmedic inspection performed on August 27th - 28th, 2020, 5 critical , 14 major and 6 other deficiencies were identified. the deficiencies included: - insufficient control over the air quality of clean rooms; - incomplete qualification of the air handling system of some of the clean rooms; - incomplete validation of sterile filtration operations of aseptically manufactured products; - inadequate frequency of media fill (less than 2x/year) on some of the production lines; - deviation occurring in the context of media fills were not closed in a timely manner (note, however, that the deviations did not concern turbidity); - inadequate deviation management - quality maintenance and qualification status of equipment is not stat of the art.</p>
<p>Action taken/proposed by the NCA :</p> <p>Revocation of the marketing authorisation(s) Marketing authorisation holders of products that have been manufactured by Legacy Pharmaceuticals Switzerland GmbH should check if there is a need to request GMP-relevant documentation on their products from Legacy, and/or retention/reference and stability programme samples should be transferred.</p>

Recall of batches already released

Swissmedic will initiate a recall of all batches of sterile products that are on the Swiss market, with the exception of products that are critical due to its therapeutic use and/or availability of alternatives.

Additional comments : The company is not existing anymore and is therefore not in a position to accept or reply to any direct correspondence. There will be no further update to the NCR.

Teleconference Date :	Teleconference Time (CET) :	Dial in no. :
------------------------------	------------------------------------	----------------------

2020-09-30

Name and signature of the authorised person of the Competent Authority of Switzerland

Confidential**Swissmedic, Swiss Agency for Therapeutic Products**Tel : **Confidential**Fax : **Confidential**

The EudraGMDP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is provided by the National Competent Authorities (NCA) of the EEA. For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage it might occur to you and/or any other third party) arising out of or in connection with the information on this database. Any questions about the content should be addressed to the relevant NCA. Please [click here](#) to get list of NCA's.

Due to the restrictions caused by COVID-19, the period of validity of MIA's, WDA's, GMP and GDP certificates is automatically extended until the end of 2021. On-site inspections will resume as soon as there is a consensus that the period of the public health crisis has passed. The clarifying remark section of individual MIA's, WDA's, GMP and GDP certificates will indicate any exceptions. Competent authorities reserve the right to inspect a manufacturing site should the need arise.

For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI

[EMA © 2014. EudraGMDP 6.4.9.7 build 2021/04/12 09:50]

Prodotto	AIC n.	Lotto	Scad.
Cefixima Aurobindo 400 mg compresse rivestite con film - 5 compresse	044331015	EXMTS9035A	06/2021
Cefixima Aurobindo 400 mg compresse rivestite con film - 5 compresse	044331015	EXMTS9035E	06/2021
Cefixima Aurobindo 400 mg compresse rivestite con film - 5 compresse	044331015	EXMTS9048A	09/2021
Cefixima Aurobindo 400 mg compresse rivestite con film - 5 compresse	044331015	EXMTS20023C	08/2022

**Ufficio Qualità dei Prodotti e Contrasto al Crimine Farmaceutico****PROVVEDIMENTO**

A: indirizzi in elenco

A seguito della segnalazione pervenuta dalla ditta Aurobindo concernente problema al confezionamento primario in confezioni del medicinale **“CEFIXIMA AUROBINDO 400 mg compresse rivestite con film”**, lotti in allegato, AIC n. **044331015** della ditta Aurobindo Pharma Italia Srl, sita a Saronno (Varese) via San Giuseppe, 102, si comunica, ai sensi dell’art. 70 del D. L.vo219/2006 e per la motivazione sopra evidenziata, il ritiro volontario, a scopo precauzionale, da parte della ditta Aurobindo Pharma Italia Srl.

La ditta Aurobindo Pharma Italia Srl ha comunicato l’avvio della procedura di ritiro che il Comando Carabinieri per la Tutela della Salute è invitato a verificare.

Il Dirigente*Domenico Di Giorgio*